CA2921507A1 - Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof - Google Patents

Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof Download PDF

Info

Publication number
CA2921507A1
CA2921507A1 CA2921507A CA2921507A CA2921507A1 CA 2921507 A1 CA2921507 A1 CA 2921507A1 CA 2921507 A CA2921507 A CA 2921507A CA 2921507 A CA2921507 A CA 2921507A CA 2921507 A1 CA2921507 A1 CA 2921507A1
Authority
CA
Canada
Prior art keywords
composition
cubilin
tumor
subject
detectable label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2921507A
Other languages
English (en)
French (fr)
Inventor
Robert Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2921507A1 publication Critical patent/CA2921507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2921507A 2013-08-22 2014-08-22 Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof Abandoned CA2921507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361868841P 2013-08-22 2013-08-22
US61/868,841 2013-08-22
PCT/US2014/052381 WO2015027205A1 (en) 2013-08-22 2014-08-22 Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2921507A1 true CA2921507A1 (en) 2015-02-26

Family

ID=52484208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2921507A Abandoned CA2921507A1 (en) 2013-08-22 2014-08-22 Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof

Country Status (5)

Country Link
US (1) US20160199500A1 (enExample)
EP (1) EP3036008A4 (enExample)
JP (1) JP2016528299A (enExample)
CA (1) CA2921507A1 (enExample)
WO (1) WO2015027205A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069147A4 (en) 2013-11-14 2017-10-11 Endocyte, Inc. Compounds for positron emission tomography
WO2016187499A1 (en) * 2015-05-20 2016-11-24 Syracuse University Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist
SG11202010217YA (en) 2018-04-17 2020-11-27 Endocyte Inc Methods of treating cancer
WO2020113130A1 (en) * 2018-11-29 2020-06-04 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
AU2020277389A1 (en) * 2019-05-20 2021-12-16 Syracuse University Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to CD206
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates
WO2025072713A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Polymyxins for delivery of agents to the kidney
WO2025072699A1 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Aminoglycosides for delivery of agents to the kidney
WO2025072672A2 (en) 2023-09-27 2025-04-03 Judo Bio, Inc. Slc6a19-targeting modulatory nucleic acid agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB733875A (en) * 1951-12-20 1955-07-20 Organon Nv Process for the manufacture of therapeutically active preparations
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
EP1435973A4 (en) * 2001-09-28 2007-05-02 Mayo Foundation SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS
RU2004115104A (ru) * 2001-10-19 2005-02-20 Томас Джефферсон Юниверсити (Us) Расар-композиции и способы визуализации злокачественных опухолей, а также их терапия
AU2003298169A1 (en) * 2003-03-24 2004-10-18 Schering Ag Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
CN101128152A (zh) * 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
JP2006350686A (ja) * 2005-06-16 2006-12-28 Seiko Epson Corp 命令セット・シミュレータ生成装置及びシミュレータ生成方法
WO2008109068A2 (en) * 2007-03-05 2008-09-12 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery
US20110092416A1 (en) * 2007-03-05 2011-04-21 Robert Patrick Doyle Vitamine B12 - Peptide Conjugates for Oral Delivery
US20140161813A1 (en) * 2012-12-12 2014-06-12 Bauer Research Foundation Methods for the diagnosis, treatment and monitoring of cancer

Also Published As

Publication number Publication date
EP3036008A1 (en) 2016-06-29
US20160199500A1 (en) 2016-07-14
WO2015027205A1 (en) 2015-02-26
EP3036008A4 (en) 2017-04-05
JP2016528299A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
US20160199500A1 (en) Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof
JP7393485B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
ES3011272T3 (en) Dual mode radiotracer and -therapeutics
EP2506876B1 (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
ES2769538T3 (es) Kit de predireccionamiento, método y agentes que se usan en éste
JP2020520902A (ja) 新規ｐｓｍａ結合剤及びその使用
JP2015523326A (ja) 放射性医薬錯体
BR112012020304B1 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido e composição farmacêutica
ES2625829T3 (es) Conjugados y sus usos en la obtención de imágenes moleculares
US12257327B2 (en) Compositions and methods for treatment and imaging using nanoparticles
US10449261B2 (en) Compositions targeting radiation-induced molecules and methods of use thereof
US20220257805A1 (en) Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
US10758612B2 (en) Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
US10066008B2 (en) Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
Lee et al. Synthesis and application of a novel cysteine-based DTPA-NCS for targeted radioimmunotherapy
Wu et al. Preclinical development of a novel [68Ga] Ga-/[177Lu] Lu-labeled agent for PSMA-targeted imaging and therapy
EP4480502A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
Elmekharam Radioimmunoconjugate for cancer molecular imaging
Lahnif Development of novel small-molecule drug conjugates for imaging and treatment of prostate cancer
KR20260026067A (ko) 탄산무수화효소 ix 양성 질환 치료 방법에 사용하기 위한 방사성 표지 화합물
Braz Mitochondria-Targeted 111In-Radiocomplexes for Auger Therapy of Prostate Cancer
WO2026039638A1 (en) Tshr-targeted radiopharmaceuticals for diagnosis and therapy of thyroid cancer
Jackson et al. Molecular Imaging of Breast Cancer Tissue via Site-Directed Radiopharmaceuticals
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство
Alrowaily La terapia radiorecettoriale con radiofarmaci peptidici

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831